drugset
drugset / Trial / NCT00500903

A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors

NCT00500903 ↗

Phase 1 Completed 87 enrolled Millennium Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of MLN8237 when given by mouth (PO) for a minimum of 7 and a maximum of 21 consecutive days, followed by a 14-day recovery period.

Timeline

Start
2007-05-15
Primary completion
2010-08-01
Completion
2011-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Alisertib Small molecule 5 mg Oral
Subject Alisertib Small molecule 10 mg Oral
Subject Alisertib Small molecule 20 mg Oral
Subject Alisertib Small molecule 25 mg Oral
Subject Alisertib Small molecule 40 mg Oral
Subject Alisertib Small molecule 50 mg Oral
Subject Alisertib Small molecule 60 mg Oral
Subject Alisertib Small molecule 70 mg Oral
Subject Alisertib Small molecule 80 mg Oral
Subject Alisertib Small molecule 110 mg Oral
Subject Alisertib Small molecule 150 mg Oral

Indications

cancer